Epigenetic reprogramming of plasmacytoid dendritic cells drives type I interferon-dependent differentiation of acute myeloid leukemias for therapeutic benefit
J. Salmon, I. Todorovski, S. J. Vervoort, K. L. Stanley, C. J. Kearney, L. Martelotto, F. Rossello, T. Semple, G. Mir Arnau, M. Zethoven, M. Bots, E. Vidacs, K. McArthur, E. Gressier, N. De Weerd, , R. W. Johnstone
The paper shows that inhibiting HDACs in AML promotes type I IFN production by pDCs, enhancing anti-tumor immunity and therapeutic benefit.
bioRxiv · Aug 23, 2020 · PreprintCancer Biology